ISSCR Urges UK Agency to Increase Enforcement for the Marketing of Unproven Products

Written By Keith Alm

The ISSCR writes to urge the Medicines and Healthcare Products Regulatory Agency to increase enforcement activities to prevent the marketing and commercialization of stem cell-related products that are unproven and do not conform to United Kingdom (UK) and European Union (EU) Advanced Therapy Medicinal Product (ATMP) regulations.

In its letter, the ISSCR expresses alarm upon learning about the surge of clinics and providers marketing unproven therapies to patients in the UK. The Society urges the prioritization of patient safety to protect public health and the commercialization of unproven stem cell products.

Read letter.

Keith Alm
Previous

ISSCR Comments on Need to Improve ClinicalTrials.gov Database to Prevent Abuse
Next

Member Spotlight: Kirstin Matthews, PhD